Previous 10 | Next 10 |
2023-11-25 09:00:00 ET Summary Novo Nordisk's stock continues to surge as greedy investors exploit surging momentum, as they fear missing out on further potential gains. The company's impressive Q3 earnings results suggest the upward momentum could continue. I also have not assess...
2023-11-25 06:58:00 ET Ozempic, Novo Nordisk 's (NYSE: NVO) blockbuster drug for type 2 diabetes, is having all sorts of unexpected impacts on the healthcare sector. With the help of similar medicines made by Eli Lilly (NYSE: LLY) , and expanded labels that allow the two com...
2023-11-25 01:43:31 ET Summary Novo Nordisk has surpassed Nestle as the largest developed-market stock outside of the US, indicating the success of the GLP-1 drug segment. The company had a strong Q3 with a 29% YoY increase in revenue and raised its full-year outlook. Analysts...
2023-11-24 13:00:31 ET More on the markets Broad Turn In Weekly Momentum Bodes Well For Stocks SPY: When Indicators Speak, The Year-End Rally Makes Little Sense 2024 U.S. Equities Outlook: Expect Bulls To Win This Round, Too Best stocks for when the 10-year T...
2023-11-24 10:32:51 ET Summary Novo Nordisk's stock price has risen by over 365% in the past 5 years, giving the company a market cap of $458 billion. Much of the valuation growth has been driven by a single drug, semaglutide. Semaglutide is approved in T2D as Ozempic, and in ...
2023-11-23 09:05:00 ET Eli Lilly (NYSE: LLY) isn't as popular a stock as Tesla (NASDAQ: TSLA) , and it might seem unlikely that the pharma company could ever grow to become larger than the hottest car stock of the decade so far. Nonetheless, thanks to a handful of ongoing dr...
2023-11-23 02:38:24 ET Summary Merck is a legacy drugmaker with a history of fat margins and occasional robust growth. The company is entering a new growth phase, making it a good investment opportunity. Merck has a low forward P/E ratio and strong growth prospects, making it ...
2023-11-21 09:50:06 ET More on NASDAQ Composite Index: Investors Beware: AI Is Moving More Rapidly Into Government Decision-Making Why Selling The Nasdaq Rally Is Still Valid Bitcoin Breakdown Signals New Bear Market Lows To Come For Stocks S&P falls afte...
2023-11-21 07:45:31 ET More on Medtronic Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings Medtronic Stock Is Simply Too Cheap To Ignore Medtronic Faces Potential Decline Despite Financial Strength Medtronic Non-GAAP EPS of $1.25 beats by $...
2023-11-21 05:30:00 ET All eyes have been on Eli Lilly (NYSE: LLY) in recent times as it prepared to increase its earnings potential in the billion-dollar weight-loss treatment market. Lilly already has generated blockbuster revenue from Mounjaro, a diabetes drug doctors have also p...
News, Short Squeeze, Breakout and More Instantly...
Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity PR Newswire Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization , oral diuret...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...